Angiopoietin-2 in Adults with Congenital Heart Disease and Heart Failure

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Lukasz, Alexander ^a,b   Beutel, Gernot ^a   Kümpers, Philipp ^b   Denecke, Agnieszka ^a   Westhoff Bleck, Mechthild ^a   Schieffer, Bernhard ^a   Bauersachs, Johann ^a   Kielstein, Jan T ^a   Tutarel, Oktay ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART FAILURE; HEART SINGLE VENTRICLE; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS;

ADULT; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; EXERCISE; FEMALE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HEART FUNCTION TESTS; HEART VENTRICLES; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879488245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066861     Document Type: Article

References (32)

1. Shaddy RE, Webb G, (2008) Applying heart failure guidelines to adult congenital heart disease patients. Expert Rev Cardiovasc Ther 6: 165-174.
2. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, et al. (2005) Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 112: 828-835.
3. Norozi K, Wessel A, Buchhorn R, Alpers V, Arnhold JO, et al. (2007) Is the Ability index superior to the NYHA classification for assessing heart failure?: comparison of two classification scales in adolescents and adults with operated congenital heart defects. Clin Res Cardiol 96: 542-547.
4. Larsson DA, Meurling CJ, Holmqvist F, Waktare JE, Thilen UJ, (2007) The diagnostic and prognostic value of brain natriuretic peptides in adults with a systemic morphologically right ventricle or Fontan-type circulation. Int J Cardiol 114: 345-351.
5. Bolger AP, Coats AJ, Gatzoulis MA, (2003) Congenital heart disease: the original heart failure syndrome. Eur Heart J 24: 970-976.
6. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, et al. (2002) Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106: 92-99.
7. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442.
8. Eindhoven JA, van den Bosch AE, Boersma E, Roos-Hesselink JW (2012) The usefulness of brain natriuretic peptide in simple congenital heart disease- a systematic review. Cardiol Young: 1-10.
9. Eindhoven JA, van den Bosch AE, Jansen PR, Boersma E, Roos-Hesselink JW, (2012) The usefulness of brain natriuretic Peptide in complex congenital heart disease: a systematic review. J Am Coll Cardiol 60: 2140-2149.
10. Garg R, Raman SV, Hoffman TM, Hayes J, Daniels CJ, (2008) Serum markers of systemic right ventricular function and exercise performance. Pediatr Cardiol 29: 641-648.
11. Giannakoulas G, Dimopoulos K, Bolger AP, Tay EL, Inuzuka R, et al. (2010) Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol 105: 869-873.
12. Tousoulis D, Charakida M, Stefanadis C, (2005) Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 100: 347-353.
13. Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, et al. (2008) Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 117: 3020-3030.
14. Tutarel O, Denecke A, Bode-Boger SM, Martens-Lobenhoffer J, Lovric S, et al. (2012) Asymmetrical dimethylarginine-more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease. PLoS One 7: e33795.
15. Brindle NP, Saharinen P, Alitalo K, (2006) Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 98: 1014-1023.
16. Fiedler U, Augustin HG, (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27: 552-558.
17. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, et al. (2000) Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 86: 24-29.
18. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, et al. (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275: 9102-9105.
19. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, et al. (2003) Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278: 1721-1727.
20. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, et al. (2004) The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150-4156.
21. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY, (2004) Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 43: 423-428.
22. Eleuteri E, Di Stefano A, Tarro Genta F, Vicari C, Gnemmi I, et al. (2011) Stepwise increase of angiopoietin-2 serum levels is related to haemodynamic and functional impairment in stable chronic heart failure. Eur J Cardiovasc Prev Rehabil 18: 607-614.
23. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, et al. (2001) Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 37: 1170-1175.
24. Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, et al. (2008) Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care 12: R94.
25. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16: 777-802.
26. Dimopoulos K, Okonko DO, Diller GP, Broberg CS, Salukhe TV, et al. (2006) Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 113: 2796-2802.
27. Kim HN, Januzzi JL Jr, (2011) Natriuretic peptide testing in heart failure. Circulation 123: 2015-2019.
28. Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, et al. (2010) The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg 10: 428-433.
29. Kumpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, et al. (2010) Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 31: 2291-2300.
30. Law YM, Ettedgui J, Beerman L, Maisel A, Tofovic S, (2006) Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure. Am J Cardiol 98: 520-524.
31. Chong AY, Caine GJ, Lip GY, (2004) Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure? Eur J Clin Invest 34: 9-13.
32. Elsasser A, Schlepper M, Klovekorn WP, Cai WJ, Zimmermann R, et al. (1997) Hibernating myocardium: an incomplete adaptation to ischemia. Circulation 96: 2920-2931.